Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats (Q47336832)

14 January 2018

title

Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats (English)

1 reference

14 January 2018

0 references

1 reference

Murray A Raskind

1

1 reference

14 January 2018

Brianna L Burke

2

1 reference

14 January 2018

Norman J Crites

3

1 reference

14 January 2018

Andre M Tapp

4

1 reference

14 January 2018

Dennis D Rasmussen

5

1 reference

14 January 2018

language of work or name

English

0 references

publication date

10 May 2006

1 reference

14 January 2018

published in

Neuropsychopharmacology

1 reference

14 January 2018

volume

32

1 reference

14 January 2018

issue

2

1 reference

14 January 2018

page(s)

284-288

1 reference

14 January 2018

The impact of weight gain on quality of life among persons with schizophrenia.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Melatonin in relation to physiology in adult humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

The role of melatonin and serotonin in aging: update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Relation of body fat distribution to metabolic complications of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Diabetes mellitus in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Role of melatonin in mediating seasonal energetic and immunologic adaptations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Melatonin effect on rat body weight regulation in response to high-fat diet at middle age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Aging-dependent changes in the effect of daily melatonin supplementation on rat metabolic and behavioral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Sensitivity of adult male Djungarian hamsters (Phodopus sungorus sungorus) to melatonin injections throughout the day: effects on the reproductive system and the pineal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301093

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.NPP.1301093

1 reference

14 January 2018

1 reference

14 January 2018